Roivant Sciences CEO Gline buys $49,957 in shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Matthew Gline reported purchasing 3,315 common shares of the company on September 18, 2025. The shares were acquired at a price of $15.07, for a total transaction value of $49,957. The purchase comes as the $10.28 billion biotech company trades near its 52-week high of $16.05, having gained over 40% in the past six months. According to InvestingPro analysis, analysts have set price targets ranging from $12 to $24.

Following the transaction, Gline directly owns 17,287,081 common shares of Roivant Sciences Ltd. This insider purchase aligns with broader management confidence, as highlighted by InvestingPro’s analysis, which reveals multiple positive indicators about the company’s momentum and management actions. Subscribers can access 15+ additional ProTips and comprehensive insider trading analysis in the Pro Research Report.

In other recent news, Roivant Sciences has seen a series of positive developments. The company reported successful results from its Phase 3 VALOR trial for brepocitinib, a treatment for dermatomyositis. The trial demonstrated significant improvement in patients, with a mean Total Improvement Score of 46.5 compared to 31.2 for placebo after 52 weeks. Following these results, H.C. Wainwright raised its price target for Roivant Sciences to $20, maintaining a Buy rating, while Goldman Sachs increased its price target to $24, also keeping a Buy rating. Both firms highlighted the statistically significant outcomes of the trial as a key reason for their optimistic outlooks.

Additionally, TD Cowen reiterated its Buy rating on Roivant Sciences after a favorable court ruling in a patent dispute involving Arbutus Biopharma and Pfizer/BioNTech. The court sided with Arbutus Biopharma on several claims related to lipid nanoparticle patents. These developments underscore a period of promising advancements and legal victories for Roivant Sciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.